Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen

Key Points

• Theravance Biopharma's stock rating has been upgraded from "hold" to "strong-buy" by analysts at Wall Street Zen.
• BTIG Research increased its price target for the company from $24.00 to $25.00, reinforcing the positive outlook on Theravance Biopharma.
• The company has seen a surge in institutional investor interest, with various firms increasing their stakes in Theravance Biopharma, which now has 99.10% of its stock owned by institutional investors.

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH - Free Report) from a hold rating to a strong-buy rating in a report released on Saturday morning.

Several other analysts also recently commented on the stock. BTIG Research raised their price objective on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research note on Tuesday, June 17th. Two analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. Based on data from MarketBeat, Theravance Biopharma currently has a consensus rating of "Strong Buy" and a consensus target price of $21.33.

Theravance Biopharma Price Performance

Shares of TBPH stock traded down $0.06 on Friday, hitting $13.39. 278,312 shares of the stock traded hands, compared to its average volume of 361,425. The firm has a market cap of $674.32 million, a price-to-earnings ratio of 55.79 and a beta of 0.01. Theravance Biopharma has a 52 week low of $7.88 and a 52 week high of $14.30. The firm has a 50 day simple moving average of $11.36 and a two-hundred day simple moving average of $10.07.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the transaction, the senior vice president directly owned 336,918 shares of the company's stock, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 44,000 shares of company stock worth $491,800 over the last three months. Company insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in TBPH. Nuveen LLC purchased a new position in shares of Theravance Biopharma in the 1st quarter worth $3,348,000. Newtyn Management LLC boosted its stake in shares of Theravance Biopharma by 5.7% during the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after purchasing an additional 258,337 shares during the period. Jefferies Financial Group Inc. boosted its stake in shares of Theravance Biopharma by 1,191.9% during the 2nd quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock worth $3,054,000 after purchasing an additional 255,455 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Theravance Biopharma by 121,993.7% during the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Theravance Biopharma by 20.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after purchasing an additional 95,304 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.